May 11, 2016
Bristol-Myers Squibb Company and AbbVie has announced that the European Commission has approved Empliciti™ (elotuzumab) for treating multiple myeloma as combination therapy with dexamethasone and Revlimid® (lenalidomide) in patients who have received at least one prior therapy. Now, Empliciti is the first and only immunostimulatory antibody approved for multiple myeloma in the European Union (EU).
“At Bristol-Myers Squibb, we are committed to delivering pioneering medicines with the goal of revolutionizing the way cancer is treated for patients who inspire our work each and every day. With the approval of Empliciti in the EU, we are proud to extend our Immuno-Oncology science to multiple myeloma patients in Europe who have received at least one prior therapy,” said Emmanuel Blin, senior vice president and head of Commercialization, Policy and Operations, Bristol-Myers Squibb. “
Michael Severino, M.D., executive vice president of research and development and chief scientific officer, AbbVie, commented: “Empliciti represents an important new treatment option for patients with multiple myeloma and healthcare providers who are treating this cancer in Europe. AbbVie is proud to be part of the team that developed Empliciti and pleased to be partnering with Bristol-Myers Squibb to bring this new therapy to previously treated multiple myeloma patients.”Bristol-Myers Squibb and AbbVie Announce the Approval of Empliciti™ (elotuzumab)by European Commission for the Treatment of Multiple Myeloma last edit: 2016-05-23T20:23:38+00:00 da